readthroughSign in
Nov 17, 2026Financing3 fact check notes

Viatris completes $36.50-per-share acquisition of Pacira BioSciences

The merger closed November 17, 2026, after Viatris's tender offer drew about 66.46% of outstanding shares, triggering a mandatory conversion rate change for Pacira's 2029 convertible notes.

Following consummation of the tender offer, the remaining conditions to the merger were satisfied or waived, and the parties completed the merger on November 17, 2026, with Purchaser merging into Pacira without a stockholder vote under Section 251(h) of the Delaware General Corporation Law, leaving Pacira as the surviving corporation.1 At the effective time, Pacira became a wholly owned subsidiary of Viatris.1

Viatris said the tender offer expired as scheduled at one minute past 11:59 p.m. Eastern time on November 16, 2026, with a total of 32,929,780 shares validly tendered, representing approximately 66.46% of shares outstanding.1 At closing, each outstanding share not held by the company, Viatris, or dissenting stockholders was converted into the right to receive the $36.50 offer price.1 The filing states the total funds needed to pay for the shares and repay certain indebtedness were approximately $1.69 billion, funded by Viatris using cash on hand and short-term borrowings.1

The closing also triggered terms under Pacira's 2.125% Convertible Senior Notes due 2029. The notes, of which $287.5 million in aggregate principal amount is outstanding, were covered by a First Supplemental Indenture dated November 17, 2026.1 Holders who convert during a 35-trading-day make-whole period will receive $1,103.8914 in cash per $1,000 of principal; after that period, conversion value drops to $922.5448 per $1,000.1

Pacira also asked Nasdaq to halt trading and file for delisting of its shares.1 The prior board and several officers departed, replaced by John Miraglia and Michael Rainerman as officers and directors of the surviving corporation.1

Fact check notes

  • ImpreciseA total of 32,929,780 shares were validly tendered, representing approximately 66.46% of shares outstandingSource indicates the 66.46% figure reflects the 32,929,780 tendered shares combined with shares already owned by Purchaser/affiliates, not the tendered shares alone; entry omits this nuance.
  • Checker's noteThe claim that '32,929,780 shares validly tendered' alone represent 66.46% slightly oversimplifies the source, which indicates that figure combined with shares already owned by Purchaser/affiliates together make up 66.46%.
  • Sentence removedViatris Inc. completed its acquisition of Pacira BioSciences, Inc. on November 17, 2026, according to a Form 8-K filed that day.a corporate relationship the sources do not state

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.